Feb 28, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2023-- 2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today that it has commenced an underwritten public
Feb 10, 2023
Abecma  more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of  Abecma Abecma  is the first and only CAR T cell
Feb 01, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023, fireside chat on February 9 at 9:00am ET , the St.
Jan 09, 2023
Anticipate $470-$570M topline U.S. revenue Abecma (idecabtagene vicleucel) in 2023, shared equally with Bristol Myers Squibb (BMS) KarMMa-3 data to be presented at EBMT-EHA 5 th European CAR T-cell Meeting on February 10, 2023 ; 3L+ sBLA submission for Abecma targeted completion in Q1 Expanded